ClinicalTrials.gg
RecruitingNCT05126472Updated Nov 16, 2026

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

A Phase 1/2 interventional study of anti-CD40 antibody 2141-V11 and anti-CD40 antibody 2141-V11 in Non-muscle Invasive Bladder Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1/2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.
Updated Nov 16, 2026Eligibility revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Planned enrollment
33rd of 93
115 · median 55
Started
2021
with 7 others
Phase 1/2
21 of 114
6 open now
Primary completion
2027-11
later than 22 of 59 live
Registered
57th of 114
by date
Lead sponsor
4 of 114
Memorial Sloan Kettering Cancer Center

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 33rd largest by planned enrollment of the 93 interventional ones that give a count, is one of 8 that started in 2021, is one of 21 in phase 1/2, reaches primary completion later than 22 of the 59 other live ones, and was the 57th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have the standard surgical procedure to remove the bladder. The researchers will test different doses of 2141-V11 to see which dose is safest in people. The researchers will also do tests to see how the body absorbs, distributes, and gets rid of 2141-V11. This study is one of the first to test 2141-V11 in people, and the first to test 2141-V11 delivered through a catheter into the bladder.

Read the detailed description

If during Period 1 treatment, the treating physician notices recurrent disease in the bladder, the patient should undergo a biopsy or TURBT. If the pathology returns as HG Ta or CIS, the patient can resume treatment. If pathology returns as HG T1, the patient will be removed from treatment. If a high-grade recurrence occurs during period 2 or 3 treatments, the patient will be removed from treatment.

Cohort B is organized into two parts. Cohort B Part 1 is the completed safety assessment of fixed-dose intratumoral 2141-V11 (10 mg) monotherapy. Cohort B Part 2 is a randomized, open-label, pilot Phase II expansion employing a selection design to evaluate the clinical efficacy of intratumoral 2141-V11 (10 mg) in combination with intravesical gemcitabine (2000 mg in 100 mL) compared to intravesical gemcitabine monotherapy (2000mg in 100 mL) in subjects with BCG-naïve high-grade Ta NMIBC. Subjects will be randomized 1:1 to the combination arm or the gemcitabine monotherapy arm.

***Continuation of Inclusion/Exclusion Criteria

Known additional malignancy that has had progression or has required active treatment in the last three years. Exceptions include:

  • Basal cell carcinoma of the skin
  • Squamous cell carcinoma of the skin that has undergone potentially curative therapy
  • In situ cervical cancer
  • History of prostate cancer treated with definitive intent (surgical or radiation therapy), provided that the following criteria are met: stage T2N0M0 or lower with a Gleason score ≤7 and prostate-specific antigen (PSA) undetectable for at least 1 year while off androgen deprivation therapy, that was either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to study enrollment
  • Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Ongoing immune related adverse event ≥ grade 2, or who require > 10 mg/day prednisone (or equivalent) to treat immune related adverse event. Note: patients who are on stable doses of physiologic corticosteroid replacement only (i.e.,hydrocortisone \< 50 mg in a 24-hour period, or equivalent) are eligible.

    • Diagnosis of immunodeficiency, concurrent immune suppressive disease, or is receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 4 weeks prior to the planned first dose of trial treatment. The use of physiologic doses of corticosteroids as replacement therapy (for adrenal or pituitary insufficiency, etc.) is acceptable. Topical and inhaled corticosteroids in standard doses are acceptable.
    • Known contraindications to intravesical therapy:
  • Febrile illness, symptomatic urinary tract infection, or persistent gross hematuria
  • Traumatic catheterization or gross hematuria on day of treatment

    • Active infection requiring systemic therapy, including active or intractable urinary tract infection within 4 weeks prior to the first dose of trial treatment
    • Severe infection within 4 weeks prior to the first dose of trial treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
    • History of (non-infectious) pneumonitis that required steroids or current pneumonitis
    • History of Human Immunodeficiency Virus (HIV) infection (e.g., positive HIV-1/2 antibodies)
    • Active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C [e.g., HCV RNA (qualitative) detected] infection; subjects with past/resolved Hepatitis B Virus (HBV) infection (defined as having a negative HBsAg and a positive antibody to Hepatitis B coreantigen) or Hepatitis C Virus (HCV) infection are eligible only if polymerase chain reaction (PCR) testing is negative for HBV DNA or HCV RNA, respectively (must be obtained within 28 days prior to treatment initiation) Pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment
    • History of stroke or intracranial hemorrhage within 6 months prior to enrollment
    • History of pulmonary embolism or any other thromboembolic event within 6 months prior to enrollment
    • History of undergoing an allogeneic tissue/solid organ transplant
    • History or current evidence of any condition, therapy, or laboratory abnormality that might interfere with the subject's participation for the full duration of the trial, interfere with the subject's ability to cooperate with the requirements of the trial, confound the results of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
03

Conditions studied

  • Non-muscle Invasive Bladder Cancer

Keywords

  • 2141-V11
  • 21-314
  • Gemcitabine
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohorts A and B Part 1

  • High-grade (HG) NMIBC (HG Ta, CIS, and/or T1) of urothelial histology that is unresponsive to adequate BCG therapy.
  • Stage, grade, and histology must be confirmed by the MSK Department of Pathology
  • Subjects with tumors of mixed urothelial/non-urothelial histology may be included, but urothelial carcinoma must be the predominant histology; subjects with predominant or exclusively non-urothelial histology are excluded
  • In those subjects with CIS, the CIS must be present on the tumor sample from the most recent cystoscopy/TURBT
  • In this context, adequate BCG therapy is defined as at least one of the following:
  • At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy
  • At least five of six doses of an initial induction course plus at least two of six doses of a second induction course
  • Disease unresponsive to adequate BCG therapy is defined as the following. Suspected recurrence from suspicious cytology or cystoscopy, and later confirmed via TURBT, is acceptable:
  • Persistent or recurrent CIS alone or with recurrent Ta/T1 disease (noninvasive papillary disease/tumor invades the subepithelial connective tissue) within 12 months of completion of adequate BCG therapy
  • Recurrent HG Ta/T1 disease within 6 months of completion of adequate BCG therapy
  • HG T1 disease at the first evaluation following an induction BCG course

Cohort C:

  • Muslce invasive bladder cancer cT2-T4aN0-2 that has a predominant urothelial histology.
  • Stage, grade, and histology must be confirmed by the MSK Department of Pathology
  • Subjects with tumors of mixed urothelial/non-urothelial histology may be included, but urothelial carcinoma must be the predominant histology; subjects with predominant or exclusively non-urothelial histology are excluded

Cohort A and B Only:

  • In subjects with papillary tumors (Ta and T1), a complete TURBT must have been performed.

This is characterized by:

  • Attainment of a visually complete resection of all papillary tumors (Ta and T1)
  • Residual CIS not amenable to complete transurethral resection is acceptable
  • Receipt of restaging transurethral resection for any tumor with invasion into the lamina propria (HG T1) as part of standard care, with documented presence of uninvolved detrusor muscle.
  • Most recent cystoscopy/TURBT must have been performed within 6 months of the first dose of trial treatment.
  • Absence of urothelial carcinoma involving the upper urinary tract (documented by radiological imaging or ureteroscopy).
  • Have elected not to undergo or are considered ineligible for radical cystectomy, as determined by the treating surgeon. Reasons for ineligibility or refusal of radical cystectomy should be discussed with the subject as part of the process.
  • Ineligibility factors for radical cystectomy may include, but are not limited to:
  • Cardiovascular disease (e.g., recent acute coronary syndrome, arrhythmia, heart failure)
  • that would preclude a safe surgical procedure, as determined by the treating surgeon
  • Poor performance status
  • Prior major abdominal and pelvic surgery that would preclude a safe surgical procedure, as determined by the treating surgeon

Cohort C Only:

  • Are willing to undergo a standard of care examination under anesthesia or cystoscopy within four weeks of scheduled radical cystetomy.
  • Patients must have received 3-4 cycles of Enfortumab Vedotin and pembrolizumab
  • Age ≥18 years on day of signing informed consent.
  • (ECOG) performance status ≤2 / performance status ≥60%, as assessed within 28 days prior to treatment initiation.
  • Required values for screening laboratory tests, performed within 28 days prior to treatment initiation:

(ANC) ≥1000/mm3

  • >75,000/mm3 without
  • >8 g/dL
  • >40 mL/min for the dose-escalation phases, >25 mL/min for the dose expansion phases (estimated can also be used in place of creatinine clearance)
  • /ALT ≤3 times the institutional (ULN)
  • Total ≤1.5 times the institutional ULN

    • Female subjects of must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study treatment.
    • Female subjects will be considered of non- if any of the following:
    • [defined as at least 12 months with no menses without an alternative medical cause; in women \<45 years of age a high follicle stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
    • Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening
    • Has a congenital or acquired condition that prevents childbearing
    • Male and female subjects of childbearing potential must agree, if participating in sexual activity that could lead to pregnancy, to use of an adequate method of contraception from the day of study medication initiation (or 14 days prior to the initiation of study medication for oral contraception) throughout the study period up to 120 days after the last dose of trial therapy. Subjects should be informed that taking the study medication(s) may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study.

      o Male subjects will be considered of non-reproductive potential if they have azoospermia (whether due to vasectomy or an underlying medical condition). Female subjects will be considered of non-reproductive potential if as described above. Acceptable methods of contraception:

    • Single method (one of the following is acceptable): intrauterine device, vasectomy of a female subject's male partner, or contraceptive rod implanted into the skin
    • Combination method (requires use of two of the following): diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide), cervical cap with spermicide (nulliparous women only), contraceptive sponge (nulliparous women only), male condom or female condom (cannot be used together), or hormonal contraceptive [oral contraceptive pill (estrogen/progestin pill or progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection
    • Male subjects must agree not to donate sperm during and after the study
    • Able to comply with the treatment schedule as determined by the participant and the licensed practitioner.

Cohort B Part 2

  • Subjects with BCG-naïve High-grade Ta NMIBC are eligible. BCG-naïve NMIBC is defined as patients with no prior BCG exposure or no BCG treatment within 2 years of trial start.

    • Stage, grade, and histology must be confirmed by the MSK Department of Pathology
    • Subjects with tumors of mixed urothelial/non-urothelial histology may be included, but urothelial carcinoma must be the predominant histology; subjects with predominant or exclusively non-urothelial histology are excluded
  • A complete TURBT must have been performed, as characterized by:

    o Attainment of a visually complete resection of all tumors

  • Most recent cystoscopy/TURBT must have been performed within 60 days of the first dose of trial treatment
  • Absence of urothelial carcinoma involving the upper urinary tract (documented by radiological imaging or ureteroscopy)
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 / Karnofsky performance status ≥60%, as assessed within 28 days prior to treatment initiation
  • Required values for screening laboratory tests, performed within 28 days prior to treatment initiation:

    • Absolute neutrophil count (ANC) ≥1000/mm3 independent of growth factor support
    • Platelets >75,000/mm3 without receiving transfusion within 4 weeks prior to screening
    • Hemoglobin >8 g/dL without receiving transfusion within 4 weeks prior to screening
    • Creatinine clearance (measured or calculated per institutional standard) >40mL/min; estimated GFR can also be used in place of creatinine clearance
    • AST/ALT ≤3 times the institutional upper limit of normal (ULN)
    • Total bilirubin ≤1.5 times the institutional ULN (except for participants with Gilbert's Syndrome or of non-hepatic origin)
  • Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study treatment.

    o Female subjects will be considered of non-reproductive potential if any of the following: oPostmenopausal [defined as at least 12 months with no menses without an alternative medical cause; in women \<45 years of age a high follicle stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.] Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening

  • Has a congenital or acquired condition that prevents childbearing
  • Male and female subjects of childbearing potential must agree, if participating in sexual activity that could lead to pregnancy, to use of an adequate method of contraception from the day of study medication initiation (or 14 days prior to the initiation of study medication for oral contraception) throughout the study period up to 120 days after the last dose of trial therapy. Subjects should be informed that taking the study medication(s) may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study.

    • Male subjects will be considered of non-reproductive potential if they have azoospermia (whether due to vasectomy or an underlying medical condition). Female subjects will be considered of non-reproductive potential if as described above.
    • Acceptable methods of contraception:
  • Single method (one of the following is acceptable): intrauterine device, vasectomy of a female subject's male partner, or contraceptive rod implanted into the skin
  • Combination method (requires use of two of the following): diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide), cervical cap with spermicide (nulliparous women only), contraceptive sponge (nulliparous women only), male condom or female condom (cannot be used together), or hormonal contraceptive [oral contraceptive pill (estrogen/progestin pill or progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection]
  • Male subjects must agree not to donate sperm during and after the study
  • Willing and able to provide written informed consent/assent for the trial
  • Able to comply with the treatment schedule as determined by the participant and the licensed practitioner

Exclusion criteria

Exclusion Criteria:

(Cohort A and B) Part 1

  • History of or currently being treated for muscle-invasive (T2, T3, T4) locally-advanced non-resectable or urothelial carcinoma.
  • Evidence of concurrent extravesical (i.e., urethra, ureter, or renal pelvis) urothelial cell carcinoma.
  • Concurrent anti-cancer therapy, including agents

Exceptions include:

  • Cohorts A and B Exceptions: Subjects on topical therapy (e.g. topical 5-
  • Cohort C Exceptions: Subjects on topical therapy (e.g. topical 5-fluorouracil) and chemotherapy (e.g. cisplatin and gemcitabine)
  • Has undergone any intervening intravesical chemotherapy or immunotherapy from the time of most recent cystoscopy/TURBT to starting trial treatment (a single dose of intravesical treatment given as part of the most recent cystoscopy/TURBT, during the screening period, such as with chemotherapy as per local/regional practices, is acceptable).
  • Have received any other neoadjuvant treatment other than Enfortumab Vedotin and pembrolizumab for muscle invasive bladder cancer
  • Has had prior chemotherapy, targeted small molecule therapy, cytokine therapy, or radiation therapy within 2 weeks prior to the first dose of trial treatment or who has not recovered (i.e., Grade ≤1 or at baseline) from AEs due to a previously administered agent.

    °Subjects with Grade ≤2 neuropathy or Grade ≤2 alopecia are an exception to this criterion and may qualify for the study

  • Major surgery or a wound that has not fully healed within 4 weeks prior to the first dose of trial treatment.

Rash from treatment \< or = grade 2 for at least 1 month prior to enrollment.

  • Patients who develop a dermatologic toxicity attributed to enfortumab vedotin and/or pembrolizumab that requires ongoing treatment with oral or systemic or immune-modulating biologic therapies are not eligible to receive intratumoral 2141-V11.

    • Patients receiving dupilumab must have received their last dose of dupilumab at least 6 weeks prior to administration of 2141-V11.
    • Patients receiving any other immune-modulating biologic therapies for management of dermatologic toxicities are not eligible. ° If subject has undergone major surgery greater than 4 weeks prior, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting trial therapy

      • Refer to detail description for the rest of the Inclusion/Exclusion criteria
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    (Cohort A) anti-CD40 antibody 2141-V11

    Intravesically or intratumorally) of an anti-CD40 agonist antibody (2141-V11) for the treatment of subjects with BCG-unresponsive NMIBC who are considered ineligible for or have elected not to undergo radical cystectomy.

    Drug: anti-CD40 antibody 2141-V11

  • Experimental
    (Cohort B) Part 1 2141-V11, a fixed dose of 10mg , Part 2 Gemcitabine

    Intratumoral 2141-V11 will be administered at the fixed dose of 10 mg established in Cohort B Part 1. Patients enrolled in Cohort B Part 2 will be randomized 1:1 to one of two treatment arms: Arm 1 (intravesical gemcitabine 2000 mg in 100 mL plus intratumoral 2141-V11 10 mg) or Arm 2 (intravesical gemcitabine 2000 mg in 100 mL monotherapy).

    Drug: anti-CD40 antibody 2141-V11 · Drug: Intravesical Gemcitabine · Drug: Intravesical Gemcitabine with anti-CD40 antibody 2141-V11

  • Experimental
    (Cohort C) expansion cohort 10 mg of 2141-V11

    For patients in Cohort C, 10 mg of 2141-V11 will be administered as an intratumoral injection during standard of care cystoscopy no sooner than day 22 of the last cycle of neoadjuvant enfortumab vedotin + pembrolizumab and prior to and within four weeks of planned radical cystectomy.

    Drug: anti-CD40 antibody 2141-V11

Interventions

  • Druganti-CD40 antibody 2141-V11

    Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points.

  • Druganti-CD40 antibody 2141-V11

    Cohort B Part 1 Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 14 and week 26 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points.

  • Druganti-CD40 antibody 2141-V11

    Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination no sooner than 22 days of the last cycle of neoadjuvant therapy with enfortumab vedotin and pembrolizumab and prior to and within 4 weeks of planned radical cystectomy.

  • DrugIntravesical Gemcitabine

    Cohort B Part 2 is a nonblinded, randomized prospective trial to determine whether the combination of gemcitabine with 2141-V11 is more efficacious than gemcitabine monotherapy in patients with BCG-naïve HG Ta NMIBC

  • DrugIntravesical Gemcitabine with anti-CD40 antibody 2141-V11

    Cohort B Part 2 is a nonblinded, randomized prospective trial to determine whether the combination of gemcitabine with 2141-V11 is more efficacious than gemcitabine monotherapy in patients with BCG-naïve HG Ta NMIBC

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. MTD/RP2D (Cohort A)

    The MTD will be defined as the dose level at which the estimated DLT rate from the MCRM model is closest to the target acceptable rate of 20%. If an MTD is not found after the full dose escalation study has been completed, the next dose recommended by the MCRM algorithm will be considered the RP2D. A DLT will be defined as the occurrence of any clinically significant grade 3 or 4 AE (per CTCAE version 5.0) within the DLT evaluation period that is considered by the Principal Investigator or designee to be possibly, probably, or definitely related to 2141-V11.

    Time frame: 2 years

  2. Reported number of adverse events from baseline (start of 2141-V11 administration) up until the last follow-up visit after 2141-V11 administration (Cohort B)

    AE severity should be graded using CTCAE version 5.0.

    Time frame: 1 year

  3. recurrence-free survival (RFS) Cohort B Part 2

    Time frame: 2 years

  4. Progression of disease

    in all subjects will be defined as development of metastatic disease or death following radical cystectomy

    Time frame: 2 years

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Bernard Bochner, MD · Contact646-422-4387
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Bernard Bochner, MD · Contact646-422-4387
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Bernard Bochner, MD · Contact646-422-4387
  • Memorial Sloan Kettering Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Bernard Bochner, PhD · Contact646-422-4387
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    East White Plains, New York 10604, United States
    Recruiting
    • Bernard Bochner, MD · Contact646-422-4387
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Bernard Bochner, MD · Contact646-422-4387
    • Eugene Pietzak, MD · Contact646-422-4781
    • Bernard Bochner, MD · Principal investigator
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Bernard Bochner, MD · Contact646-422-4387
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Nov 2027, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2021
First posted
Nov 19, 2021
StartActual
Nov 8, 2021
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) · East White Plains, United States
Show 1 removed
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, United States
Nov 16, 2026
Eligibility
6 inclusion criteria edited; 1 exclusion criterion edited, 3 added
What changed in the criteria
Inclusion criteria
  • Editedo Absolute neutrophil count (ANC) ≥1000/mm3 independent of growth factor support
  • Editedo Platelets >75,000/mm3 without receiving transfusion within 4 weeks prior to screening
  • Editedo Hemoglobin >8 g/dL without receiving transfusion within 4 weeks prior to screening
  • Editedo Creatinine clearance (measured or calculated per institutional standard) >40mL/min; estimated GFR can also be used in place of creatinine clearance
  • Editedo AST/ALT ≤3 times the institutional upper limit of normal (ULN)
  • Editedo Total bilirubin ≤1.5 times the institutional ULN (except for participants with Gilbert's Syndrome or of non-hepatic origin)
Exclusion criteria
  • AddedRash from treatment < or = grade 2 for at least 1 month prior to enrollment.
  • AddedPatients who develop a dermatologic toxicity attributed to enfortumab vedotin and/or pembrolizumab that requires ongoing treatment with oral or systemic corticosteroids or immune-modulating biologic therapies are not eligible to receive intratumoral 2141-V11.
  • AddedPatients receiving dupilumab must have received their last dose of dupilumab at least 6 weeks prior to administration of 2141-V11.
  • EditedPatients receiving any other immune-modulating biologic therapies for management of dermatologic toxicities are not eligible. ° If subject has undergone major surgery greater than 4 weeks prior, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting trial therapy
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    1 site added, 1 site removed
    Show site
    • Memorial Sloan Kettering Westchester (Limited Protocol Activities) · East White Plains, United States
    Show 1 removed
    • Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, United States
    Eligibility 6 inclusion criteria edited; 1 exclusion criterion edited, 3 added
    What changed in the criteria
    Inclusion criteria
    • Editedo Absolute neutrophil count (ANC) ≥1000/mm3 independent of growth factor support
    • Editedo Platelets >75,000/mm3 without receiving transfusion within 4 weeks prior to screening
    • Editedo Hemoglobin >8 g/dL without receiving transfusion within 4 weeks prior to screening
    • Editedo Creatinine clearance (measured or calculated per institutional standard) >40mL/min; estimated GFR can also be used in place of creatinine clearance
    • Editedo AST/ALT ≤3 times the institutional upper limit of normal (ULN)
    • Editedo Total bilirubin ≤1.5 times the institutional ULN (except for participants with Gilbert's Syndrome or of non-hepatic origin)
    Exclusion criteria
    • AddedRash from treatment < or = grade 2 for at least 1 month prior to enrollment.
    • AddedPatients who develop a dermatologic toxicity attributed to enfortumab vedotin and/or pembrolizumab that requires ongoing treatment with oral or systemic corticosteroids or immune-modulating biologic therapies are not eligible to receive intratumoral 2141-V11.
    • AddedPatients receiving dupilumab must have received their last dose of dupilumab at least 6 weeks prior to administration of 2141-V11.
    • EditedPatients receiving any other immune-modulating biologic therapies for management of dermatologic toxicities are not eligible. ° If subject has undergone major surgery greater than 4 weeks prior, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting trial therapy
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05126472
Collaborators
Pin Down Bladder Cancer Research Foundation, Rockefeller University
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Nov 8, 2021
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Bernard Bochner, MD
Contact
bochnerb@mskcc.org
646-422-4387
Eugene Pietzak, MD
Contact
646-422-4781
Bernard Bochner, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion